Ana S.
- Country
- Portugal
- Department
- N/A
Research Overview
- Evaluation of Semaglutide in Patients with Non-Cirrhotic Non-Alcoholic Steatohepatitis and Fibrosis Stages 2 or 3: A Randomized, Placebo-Controlled Trial
- Efficacy and Safety of Obefazimod for Induction in Adults with Moderately to Severely Active Ulcerative Colitis: Randomized, Double‑Blind, Placebo‑Controlled III Trial
Data & Insights
Has run more than one trial at 7 of 161 partner sites.
Specializations
Hepatology Focus
The investigator specializes in the study of non-alcoholic steatohepatitis (NASH), conducting research into innovative therapeutic approaches for this liver condition. Their work centers on evaluating treatments that aim to improve liver histology and reduce disease progression.
- Liver Disease Management
- Metabolic Liver Disorders
- Hepatic Fibrosis
Their research extends to investigating clinical outcomes in patients with varying stages of liver fibrosis.
Metabolic Research
The investigator focuses on the intersection of metabolic disorders and liver disease, particularly exploring novel therapeutic agents. Their expertise includes evaluating treatments that target both metabolic and hepatic pathways.
- Metabolic Syndrome
- Liver-Related Clinical Events
- Disease Progression Assessment
Their work encompasses the evaluation of therapeutic interventions in patients with established liver disease.
Clinical Assessment
The investigator specializes in histological evaluation of liver disease, focusing on comparative assessment methods. Their expertise includes monitoring disease progression and treatment response in chronic liver conditions.
- Liver Histology Analysis
- Disease Stage Assessment
- Treatment Response Evaluation
Their research methodology incorporates advanced assessment techniques for liver disease progression.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.